A Pennsylvania based biotechnology company announced positive efficacy results for an open-label Phase 2 trial of VGX-3100 to treat HPV-16 and HPV-18-associated vulvar dysplasia.
A 25 percent or more reduction in HPV-16/18-associated vulvar HSIL (high-grade squamous intraepithelial lesion) was observed for 63 percent of trial participants (12 of 19) treated with VGX-3100 at six months post-treatment, stated INOVIO Pharmacuticals, Inc.’s press release issued on January 6, 2021.
Read More
